Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 6/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.51 |
| ▸ | PTGFR | P43088 | 2/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242419 | 1.00 | PTGIR (0.53) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL7241138 | 0.91 | PTGIR (0.56) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL7241141 | 0.91 | PTGIR (0.56) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL7247870 | 0.90 | PTGER3 (0.49) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL7247872 | 0.90 | PTGER3 (0.49) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL7243195 | 0.90 | PTGIR (0.45) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL7243200 | 0.90 | PTGIR (0.45) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL5683357 | 0.87 | PTGER3 (0.54) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL5683377 | 0.87 | PTGER3 (0.54) | PTGIRPTGER2PTGER3PTGFRPTGER4 | |
| SCHEMBL5683369 | 0.87 | PTGER3 (0.54) | PTGIRPTGER2PTGER3PTGFRPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | claimed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | claimed |
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | PTGIR 5/4885PTGER2 1/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.